MENU
ACET
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

ACET stock forecast, quote, news & analysis

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer... Show more

ACET
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement

Adicet Bio (ACET) Stock Analysis: Clinical-Stage Biotech Advancing Allogeneic Cell Therapies

Key Takeaways

  • Adicet Bio develops off-the-shelf gamma delta T-cell therapies targeting cancer and autoimmune diseases.
  • Recent quarterly results showed narrower-than-expected losses, supporting ongoing pipeline progress.
  • Analyst sentiment remains largely positive with multiple Buy ratings maintained through mid-2026.
  • Stock has traded in a relatively contained range amid broader biotech sector dynamics.
  • Key upcoming catalysts include additional clinical data readouts and financing runway into 2027.

Current Market Snapshot

Adicet Bio shares have exhibited measured trading activity over recent sessions, reflecting the typical volatility of early-stage biotechnology companies. The stock continues to draw attention from investors focused on innovative cell therapy platforms, with positioning influenced by sector rotation and clinical milestones rather than broad market swings.

Adicet Bio (ACET) Business Overview and Competitive Position

Adicet Bio is a clinical-stage biotechnology company specializing in allogeneic gamma delta T-cell therapies. Its lead programs target hematologic malignancies and solid tumors using engineered cells designed for off-the-shelf administration, potentially offering advantages over autologous approaches in scalability and accessibility. The company’s differentiated platform leverages innate immune system properties to pursue improved safety and efficacy profiles. Investors track Adicet for its progress in expanding the addressable patient population through these novel modalities.

Recent Developments Driving ACET

In the past month, Adicet reported first-quarter financial results that beat consensus estimates on the bottom line, highlighting disciplined cash management. Analyst firms including Wedbush, Canaccord Genuity, and JonesTrading reaffirmed Buy ratings, underscoring confidence in the company’s cash runway extending into 2027 and its differentiated pipeline. Earlier in the quarter, the company completed an equity transaction that bolstered its balance sheet. No major regulatory setbacks or partnership announcements emerged during the period, keeping focus on clinical execution.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases a curated selection of top-performing artificial intelligence trading bots that actively trade thousands of tickers. While Tickeron offers hundreds of AI-driven strategies spanning various timeframes and risk profiles, only the strongest and most relevant bots surface in this dynamic section. Performance metrics, strategy types, and historical results help users compare options. The platform provides a neutral environment for exploring automated trading approaches. Explore the full selection on the Trending AI Robots page.

2026 Outlook and What Investors Should Watch

Investors will monitor upcoming clinical data releases for Adicet’s lead candidates, updates on manufacturing scale-up, and any new partnership or financing activity. Broader macroeconomic factors, including interest rate trajectories and biotech funding conditions, remain relevant. Analyst price targets and rating changes will also influence sentiment, as will competitive developments in the allogeneic cell therapy space. Regulatory feedback on trial designs represents another key variable for the year ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
A.I.Advisor
a Summary for ACET with price predictions
Jul 02, 2026

ACET in upward trend: 10-day moving average crossed above 50-day moving average on June 26, 2026

The 10-day moving average for ACET crossed bullishly above the 50-day moving average on June 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ACET as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ACET just turned positive on June 18, 2026. Looking at past instances where ACET's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

ACET moved above its 50-day moving average on June 26, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACET advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ACET moved out of overbought territory on June 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ACET broke above its upper Bollinger Band on May 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ACET’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.549) is normal, around the industry mean (20.992). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ACET has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (368.009).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
published Dividends

ACET paid dividends on October 09, 2018

Adicet Bio Inc ACET Stock Dividends
А quarterly dividend of $0.01 per share was paid with a record date of October 09, 2018, and an ex-dividend date of September 21, 2018. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 134.02B. VRTX holds the highest valuation in this group at 134.02B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 1,922%. CRIS experienced the highest price growth at 56%, while EVMN experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 169%. For the same stocks of the Industry, the average monthly volume growth was 159% and the average quarterly volume growth was 242%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 54
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
ACET
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a distributor of pharmaceutical intermediate ingrediants and other industrial chemicals

Industry Biotechnology

Profile
Details
Industry
Medical Distributors
Address
131 Dartmouth Street
Phone
+1 650 503-9095
Employees
102
Web
https://www.adicetbio.com
Adicet Bio (ACET) Stock Analysis: Clinical-Stage Biotech Advancing Allogeneic Cell Therapies